Apoptosis during ZIKA Virus Infection: Too Soon or Too Late?

Jonathan Turpin1, Daed El Safadi1, Grégorie Lebeau1

  • 1Processus Infectieux en Milieu Insulaire Tropical (PIMIT), Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, France.

Insights

Zika virus (ZIKV) manipulates apoptosis, a programmed cell death, for its survival and spread. Understanding this interaction is key to developing ZIKV therapies and potential oncolytic treatments.

Area of Science:

  • Virology
  • Cell Biology
  • Immunology

Background:

  • Apoptosis is a crucial cellular defense against viral infections, aiding in viral clearance.
  • Viruses have evolved mechanisms to evade or manipulate apoptosis to ensure their replication and spread.
  • Zika virus (ZIKV) causes significant neurological issues and can persist in the genital tract, highlighting its complex interaction with host cells.

Purpose of the Study:

  • To review the intricate relationship between Zika virus infection and apoptosis.
  • To explore how ZIKV controls or is affected by apoptosis in various cell types.
  • To discuss the dual role of ZIKV-modulated apoptosis in disease pathogenesis and viral persistence.

Main Methods:

  • Literature review of studies investigating Zika virus and apoptosis.
  • Analysis of viral strategies to control host cell apoptosis.
  • Examination of the impact of apoptosis timing on ZIKV-related neuropathogenesis and persistence.

Main Results:

  • ZIKV can both induce and evade apoptosis, depending on the cellular context and infection stage.
  • Apoptosis occurring early in ZIKV infection may contribute to neuropathogenesis, while late apoptosis is linked to viral persistence.
  • The virus actively modulates host cell death pathways to facilitate its lifecycle.

Conclusions:

  • The interplay between ZIKV and apoptosis is complex, with significant implications for Zika disease.
  • Targeting ZIKV-controlled apoptosis presents a potential therapeutic strategy for Zika virus infections.
  • ZIKV's ability to modulate apoptosis suggests its potential use as an oncolytic agent in cancer therapy.